Építés alatt – nem éles oldal
Belépés
LeállítvaFázis nélkül

A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.

A legfontosabb adatok

Ki végzi
M. H MediCane Ltd.
Hol
Izrael3 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Leállítva
Résztvevők
24 fő vett részt
Kezdés
2022. okt. 12.
Befejezés
2024. márc. 10.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Medical Cannabis
  • Placebo Oil
A regiszteradat frissítve
2024. június 27.
Miért állt le
Part I: Open-label was completed.

Ki vehet részt

Életkor
50 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • Subjects are Male or Female age ≥50 years
  • Subjects have a diagnosis of major neurocognitive disorder (previously dementia) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) Criteria for at least 6 months prior to screening or a diagnosis of probable AD using the NINCDS-ADRDA clinical criteria
  • Subjects on antipsychotic medications may be included in the study
  • Subject exhibits agitation/aggression with a Neuropsychiatric Inventory (NPI-12)-agitation/aggression subdomain score of four or higher (≥4) at screening
  • Subject has a legal guardian who is able and willing to provide ICF and able to provide - information in writing. The caregiver should be spending enough time with the subject on a regular basis in order to provide valid information as requested
  • Subjects are on stable SoC for treatment of agitation and disruptive behaviors for at least 2 weeks prior to the screening visit
  • Subjects on Acetyl Choline Esterase inhibitors, antifungals, macrolide antibiotics and anti-hypertensive therapy including ACE inhibitors should be on stable doses for at least 2 weeks prior to screening visit or if changed, at least 2 weeks prior to visit 1
  • Subject's Mini Mental State Exam score (MMSE) is 24 or less at screening

Ki nem vehet részt

  • Subjects treated with one of the following medications: opiates, primidone, phenobarbitol, carbamazepine, rifampicin, rifabutin, troglitazone, hypericum perforatum, or valproic acid within 30 days from Visit 1
  • Subjects currently on medication known to interact with Cannabis-based medications are excluded; Subjects taking Cannabis-based therapies are excluded if within the past 2 weeks from Visit 1
  • Subject with any current unstable medical condition
  • Subject has any unstable condition involving fluid retention, pulmonary infiltrates, congestive heart failure, respiratory symptoms or disease, or cardiac symptoms or disease
  • Subject has epilepsy
  • Subject has a history of hypersensitivity to any cannabinoid
  • Subject has the presence or history of a primary psychotic psychiatric disorder or subject has clinically significant delusions or hallucinations secondary to the neurodegenerative disease (NPI-12 delusions or hallucinations sub-score of 4 or higher (≥4)
  • Subject has other health-related factors that could explain behavioral disturbances (electrolyte disturbances, infectious diseases, etc.)
  • Subjects with a history of addiction or drug abuse
  • Subject has one of the following hepatic /renal disorders:; Confirmed and unexplained impaired hepatic function as indicated by screening AST or ALT>3 the upper limit of normal (ULN) or total bilirubin > 2 ULN; Chronic kidney disease of Stage > 4, according to National Kidney Foundation Kidney Disease Outcome Quality Initiative guidelines for chronic kidney disease
  • Subject without a legal guardian
  • Subject suffering from delirium as defined in Appendix B - Criteria for Delirium
  • Current inpatient hospitalization
  • Subject has a satisfactory response to antipsychotic treatments

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This double-blind, placebo-controlled study is designed to assess the effectiveness of, MediCane's medical cannabis oil extracted from MediCane's proprietary strain into GMP-grade olive oil, as an add-on therapy to standard of care (SoC), in reducing agitation and disruptive behaviors in subjects with dementia including probable AD.

A vizsgálat 2 csoportja

  • MediCane's medical cannabis oilA vizsgált kezelés

    Kezelés: Medical Cannabis

  • PlaceboPlacebo, összehasonlításként

    Kezelés: Placebo Oil

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Two-part Study, Part I an Open-label; and Part II a Randomized Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MediCane's Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia Including Probable Alzheimer's Disease (AD)
A regiszteradat frissítve
2024. június 27.